VistaGen Therapeutics, Inc.

Historical 13F Holders

Symbol: VTGN
CUSIP: 92840H400
All holders as of: Q2 2026
Type: Equity
Class: COM

Reported Value, Excluding Options

Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92840H400 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Commodore Capital LP 13G/A Amendment 3	9.9%	4,244,590	13G/A Amendment 3	8/14/2026 Event 6/30/2026
Commodore Capital LP	9.9%	4,244,590
Commodore Capital Master LP	9.9%	4,244,590
Robert Egen Atkinson	9.9%	4,244,590
Michael Kramarz	9.9%	4,244,590
TCG Crossover GP I, LLC 13G/A Amendment 2	6.7%	2,960,404	13G/A Amendment 2	8/14/2026 Event 6/30/2026
TCG Crossover GP I, LLC	1.8%	740,101
TCG Crossover Fund I, L.P.	1.8%	740,101
TCG Crossover GP II, LLC	5.1%	2,220,303
TCG Crossover Fund II, L.P.	5.1%	2,220,303
Chen Yu	6.7%	2,960,404
Orbimed Advisors LLC 13G/A Amendment 2	0%	0	13G/A Amendment 2	8/14/2026 Event 6/30/2026
Orbimed Advisors LLC	0%	0
Orbimed Capital LLC	0%	0
TCG Crossover GP II, LLC 13G/A Amendment 1	10.0%	4,100,029	13G/A Amendment 1	5/15/2026 Event 3/31/2026
TCG Crossover GP I, LLC	2.6%	1,025,007
TCG Crossover Fund I, L.P.	2.6%	1,025,007
TCG Crossover GP II, LLC	7.6%	3,075,022
TCG Crossover Fund II, L.P.	7.6%	3,075,022
Chen Yu	10.0%	4,100,029
Commodore Capital LP 13G/A Amendment 2	9.9%	4,383,508	13G/A Amendment 2	2/17/2026 Event 12/31/2025
Commodore Capital LP	9.9%	4,383,508
Commodore Capital Master LP	9.9%	4,383,508
Robert Egen Atkinson	9.9%	4,383,508
Michael Kramarz	9.9%	4,383,508
Janus Henderson Group PLC 13G/A Amendment 1	0%	0	13G/A Amendment 1	2/17/2026 Event 12/31/2025
Great Point Partners, LLC 13G/A Amendment 7	4.95%	2,055,834	13G/A Amendment 7	2/17/2026 Event 12/31/2025
Great Point Partners, LLC	4.95%	2,055,834
Dr. Jeffrey R. Jay, M.D.	4.95%	2,055,834
Ms. Lillian Nordahl	4.95%	2,055,834
StemPoint Capital LP 13G/A Amendment 2	1.5%	616,749	13G/A Amendment 2	2/17/2026 Event 12/31/2025
StemPoint Capital LP	1.5%	616,749
StemPoint Capital Management GP LLC	1.5%	616,749
Michelle Ross	1.5%	616,749
Orbimed Advisors LLC 13G/A Amendment 1	4.2%	1,639,700	13G/A Amendment 1	2/17/2026 Event 12/31/2025
Orbimed Advisors LLC	3.6%	1,420,300
Orbimed Capital LLC	4.2%	1,639,700
Nantahala Capital Management, LLC 13G/A Amendment 3	4.7%	1,953,045	13G/A Amendment 3	2/13/2026 Event 12/31/2025
Nantahala Capital Management, LLC	4.7%	1,953,045
Wilmot B. Harkey	4.7%	1,953,045
Daniel Mack	4.7%	1,953,045
Vanguard Group Inc 13G/A Amendment 2	4.6%	1,824,738	13G/A Amendment 2	1/30/2026 Event 12/31/2025
Great Point Partners, LLC 13G/A Amendment 6	6.3%	2,055,834	13G/A Amendment 6	11/14/2025 Event 9/30/2025
Great Point Partners, LLC	6.3%	2,055,834
Dr. Jeffrey R. Jay, M.D.	6.3%	2,055,834
Ms. Lillian Nordahl	6.3%	2,055,834
Nantahala Capital Management, LLC 13G/A Amendment 2	10.0%	3,185,564	13G/A Amendment 2	11/14/2025 Event 9/30/2025
Nantahala Capital Management, LLC	10.0%	3,185,564
Wilmot B. Harkey	10.0%	3,185,564
Daniel Mack	10.0%	3,185,564
Orbimed Advisors LLC 13G	5.3%	1,639,700	13G	11/14/2025 Event 9/30/2025
Orbimed Advisors LLC	4.6%	1,420,300
Orbimed Capital LLC	5.3%	1,639,700
Vanguard Group Inc 13G/A Amendment 1	5.5%	1,687,735	13G/A Amendment 1	10/31/2025 Event 9/30/2025
Janus Henderson Group PLC 13G	13.6%	4,165,767	13G	9/8/2025 Event 8/29/2025
Janus Henderson Group PLC	13.6%	4,165,767
Janus Henderson Biotech Innovation Master Fund Ltd	11.7%	3,575,276
Great Point Partners, LLC 13G/A Amendment 5	6.6%	2,055,834	13G/A Amendment 5	8/14/2025 Event 6/30/2025
Great Point Partners, LLC	6.6%	2,055,834
Dr. Jeffrey R. Jay, M.D.	6.6%	2,055,834
Ms. Lillian Nordahl	6.6%	2,055,834
Great Point Partners, LLC 13G/A Amendment 4	6.7%	2,055,834	13G/A Amendment 4	5/15/2025 Event 3/31/2025
Great Point Partners, LLC	6.7%	2,055,834
Dr. Jeffrey R. Jay, M.D.	6.7%	2,055,834
Ms. Lillian Nordahl	6.7%	2,055,834
Great Point Partners, LLC 13G/A Amendment 3	6.9%	2,055,834	13G/A Amendment 3	2/14/2025 Event 12/31/2024
Great Point Partners, LLC	6.9%	2,055,834
Dr. Jeffrey R. Jay, M.D.	6.9%	2,055,834
Ms. Lillian Nordahl	6.9%	2,055,834
StemPoint Capital LP 13G/A Amendment 1	8.2%	2,328,492	13G/A Amendment 1	2/14/2025 Event 12/31/2024
StemPoint Capital LP	8.2%	2,328,492
StemPoint Capital Management GP LLC	8.2%	2,328,492
Michelle Ross	8.2%	2,328,492
Biotechnology Value Fund L P 13G/A Amendment 1	10.0%	3,084,324	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Biotechnology Value Fund L P	5.4%	1,589,495
BVF I GP LLC	5.4%	1,589,495
Biotechnology Value Fund II LP	4.4%	1,289,734
BVF II GP LLC	4.4%	1,289,734
Biotechnology Value Trading Fund OS LP	0.6%	158,606
BVF Partners OS Ltd.	0.6%	158,606
BVF GP Holdings LLC	9.4%	2,879,229
BVF Partners L P/IL	10.0%	3,084,324
BVF Inc/IL	10.0%	3,084,324
Lampert Mark N	10.0%	3,084,324
Nantahala Capital Management, LLC 13G/A Amendment 1	10.0%	2,834,336	13G/A Amendment 1	11/14/2024 Event 9/30/2024
Nantahala Capital Management, LLC	10.0%	2,834,336
Wilmot B. Harkey	10.0%	2,834,336
Daniel Mack	10.0%	2,834,336

13F Holders by Quarter

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q3	1	15.0 k	$4.62 k	$0
2026 Q2	58	11.8 M	$2.54 M	$286 k
2026 Q1	62	15.3 M	$8.18 M	$316 k
2025 Q4	65	13.8 M	$8.84 M	$1.17 M
2025 Q3	67	23.9 M	$83.7 M	$2.65 M
2025 Q2	56	15.5 M	$30.3 M	$206 k
2025 Q1	52	15.9 M	$39.0 M	$25.8 k
2024 Q4	62	15.5 M	$44.9 M	$1.19 M
2024 Q3	55	15.3 M	$45.3 M	$1.25 M
2024 Q2	50	15.2 M	$52.3 M	$1.19 M
2024 Q1	49	14.7 M	$76.9 M	$1.97 M
2023 Q4	55	16.9 M	$86.5 M	$2.64 M
2023 Q3	41	3.00 M	$15.7 M	$2.83 M
2023 Q2	34	967 k	$1.81 M	$26.9 k